Previous 10 | Next 10 |
RxSight press release ( NASDAQ: RXST ): Q2 Non-GAAP EPS of -$0.50 beats by $0.15 . Revenue of $11.4M (+132.7% Y/Y) beats by $0.85M . For further details see: RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
ALISO VIEJO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it has filed a $200 million shelf registration stat...
ALISO VIEJO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2022....
ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 ...
MedTech firm RxSight, Inc. ( NASDAQ: RXST ) announced that the U.S. Food and Drug Administration (FDA) notified the company on June 30 that the agency required additional information for the approval of its lower-cost-to-manufacture Light Delivery Device (LDD). LDD —...
The following slide deck was published by RxSight, Inc. in conjunction with this event. For further details see: Rxsight (RXST) Investor presentations - Slideshow
RxSight, Inc. (RXST) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Philip Taylor - Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Saxon - Needha...
Image source: The Motley Fool. RxSight, Inc. (NASDAQ: RXST) Q1 2022 Earnings Call May 05, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: RxSight, Inc. (RXST) Q1 2022 Earnings Call Transcript
RxSight press release (NASDAQ:RXST): Q1 Non-GAAP EPS of -$0.54 beats by $0.06. Revenue of $8.9M (+155.7% Y/Y) beats by $1.57M. Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million ($42.19M consensus), compared to the prior 2022 guidance range of $40 million to $44 millio...
ALISO VIEJO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended March 31, 2022. ...
News, Short Squeeze, Breakout and More Instantly...
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second...
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference. ...
Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of th...